Tango Therapeutics (TNGX) Interest Expenses (2020 - 2026)

Tango Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $313.6 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 1161408.16% year-over-year to $313.6 million in Q1 2026; TTM through Mar 2026 was $313.6 million, a 1161408.16% increase from a year earlier, with the FY2025 full-year figure at $186.6 million, up 19.31% from the prior year.
• Interest Expenses advanced to $313.6 million in Q1 2026 per TNGX's latest filing, from $60.7 million in the prior quarter.
• Across five years, Interest Expenses topped out at $87.9 billion in Q3 2023 and bottomed at $27000.0 in Q1 2025.
• The 5-year median for Interest Expenses is $62.6 million (2023), against an average of $8.3 billion.
• Across the five-year window, Interest Expenses tumbled 99.96% in 2024 and soared 1161408.16% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $81.0 million in 2022, then decreased by 22.71% to $62.6 million in 2023, then sank by 96.56% to $2.2 million in 2024, then jumped by 2714.84% to $60.7 million in 2025, then jumped by 416.47% to $313.6 million in 2026.
• Per Business Quant, the three latest TNGX Interest Expenses figures stand at $313.6 million (Q1 2026), $60.7 million (Q4 2025), and $59.8 million (Q3 2025).